These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17288695)

  • 1. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
    Shah M; Butler M; Bramley T; Curtice TG; Fine S
    Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS; Joyce G
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease.
    Dalal AA; Shah M; Lunacsek O; Hanania NA
    Respir Med; 2011 Oct; 105(10):1516-22. PubMed ID: 21684731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
    Stock SA; Stollenwerk B; Redaelli M; Civello D; Lauterbach KW
    J Womens Health (Larchmt); 2008 Apr; 17(3):343-54. PubMed ID: 18338965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.
    Black L; Naslund MJ; Gilbert TD; Davis EA; Ollendorf DA
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA.
    Joyce AT; Smith P; Khandker R; Melin JM; Singh A
    J Rheumatol; 2009 Apr; 36(4):743-52. PubMed ID: 19228658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
    Fillit H; Hill JW; Futterman R
    Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Service utilization and associated direct costs for bipolar disorder in 2004: an analysis in managed care.
    Stensland MD; Jacobson JG; Nyhuis A
    J Affect Disord; 2007 Aug; 101(1-3):187-93. PubMed ID: 17254637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current practice and resource utilisation in men diagnosed with premature ejaculation.
    Nuyts GD; Hill K; Jones MP
    Int J Clin Pract; 2008 Oct; 62(10):1533-40. PubMed ID: 18822023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burden of illness of hepatitis C from a managed care organization perspective.
    Armstrong EP; Charland SL
    Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT; Calhoun E; Jacobsen SJ
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes.
    Mody R; Kalsekar I; Kavookjian J; Iyer S; Rajagopalan R; Pawar V
    J Diabetes Complications; 2007; 21(2):75-83. PubMed ID: 17331855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the epidemiology and natural history of benign prostatic hyperplasia.
    Boyle P
    Prog Clin Biol Res; 1994; 386():3-18. PubMed ID: 7528398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting.
    Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A
    Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension.
    Boyle P; Napalkov P
    Scand J Urol Nephrol Suppl; 1995; 168():7-12. PubMed ID: 7541551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV; Jacobson DJ; McGree ME; Roberts RO; Lieber MM; Jacobsen SJ
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
    Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
    Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.